NASDAQ:OABI

OmniAb (OABI) Stock Forecast, Price & News

$5.19

-0.09 (-1.70%)

(As of 09/29/2023 08:53 PM ET)

Compare

Today's Range: $5.11
▼
$5.34
50-Day Range: $4.98
▼
$5.93
52-Week Range: $1.91
▼
$10.50

Volume: 925,100 shs
Average Volume: 599,446 shs
Market Capitalization: $602.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

OmniAb MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 92.7% Upside
$10.00 Price Target
Short Interest: Bearish
4.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.54
Based on 6 Articles This Week
Insider Trading: Acquiring Shares
$246,600 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.45) to ($0.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

533rd out of 970 stocks

Commercial Physical Research Industry

9th out of 14 stocks

3.5

Analyst's Opinion

Consensus Rating
OmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, OmniAb has a forecasted upside of 92.7% from its current price of $5.19.
Amount of Analyst Coverage
OmniAb has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.90% of the float of OmniAb has been sold short.
Short Interest Ratio / Days to Cover
OmniAb has a short interest ratio ("days to cover") of 9.4.
Change versus previous month
Short interest in OmniAb has recently increased by 9.22%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
OmniAb does not currently pay a dividend.
Dividend Growth
OmniAb does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OABI.

2.5

News and Social Media Coverage

News Sentiment
OmniAb has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for OmniAb this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added OmniAb to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OmniAb insiders have bought more of their company's stock than they have sold. Specifically, they have bought $246,600.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.00% of the stock of OmniAb is held by insiders.
Percentage Held by Institutions
58.73% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for OmniAb are expected to grow in the coming year, from ($0.45) to ($0.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OmniAb is -22.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OmniAb is -22.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OmniAb has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About OmniAb (NASDAQ:OABI) Stock

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

OABI Price History

30 days | 90 days | 365 days | Advanced Chart

OABI Stock News Headlines

October 1, 2023 | americanbankingnews.com

Head to Head Contrast: OmniAb (NASDAQ:OABI) versus FOXO Technologies (NYSE:FOXO)

September 30, 2023 | americanbankingnews.com

OmniAb, Inc. (NASDAQ:OABI) Receives Consensus Rating of "Buy" from Analysts

October 2, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

September 26, 2023 | msn.com

Immunovant drives OmniAb higher after data update; argenx slips

September 25, 2023 | msn.com

OmniAb: Hold For Growth

September 17, 2023 | seekingalpha.com

OABIW OmniAb, Inc. WT EXP 110127

September 5, 2023 | finance.yahoo.com

OmniAb to Participate in Two Investor Conferences in September

August 18, 2023 | finance.yahoo.com

OmniAb President Acquires 2.0% More Stock

October 2, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

August 16, 2023 | finance.yahoo.com

Need To Know: Analysts Just Made A Substantial Cut To Their OmniAb, Inc. (NASDAQ:OABI) Estimates

August 15, 2023 | finance.yahoo.com

OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript

August 13, 2023 | markets.businessinsider.com

Truist Financial Remains a Buy on OmniAb (OABI)

August 13, 2023 | finance.yahoo.com

OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know

August 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Technology Companies: Evolv Technologies Holdings (EVLV), Viavi Solutions (VIAV) and OmniAb (OABI)

August 11, 2023 | msn.com

HC Wainwright & Co. Reiterates OmniAb (OABI) Buy Recommendation

August 11, 2023 | finance.yahoo.com

OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights

August 8, 2023 | finance.yahoo.com

OmniAb Announces the Passing of Director Sunil Patel

July 31, 2023 | finance.yahoo.com

OmniAb to Report Second Quarter 2023 Financial Results on August 10

July 17, 2023 | finance.yahoo.com

With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns

June 29, 2023 | seekingalpha.com

OmniAb: Plenty Of Potential

June 5, 2023 | finance.yahoo.com

President of OmniAb Matthew Foehr Buys 22% More Shares

May 26, 2023 | seekingalpha.com

OmniAb (OABI) Investor Presentation - Slideshow

May 17, 2023 | finance.yahoo.com

OmniAb Launches OmniDeep™ at the PEGS Boston Conference and Expo

May 16, 2023 | finance.yahoo.com

President of OmniAb Matthew Foehr Buys 22% More Shares \

May 15, 2023 | seekingalpha.com

OmniAb: 6 Months In And Going Strong

May 15, 2023 | markets.businessinsider.com

SVB Securities Remains a Buy on OmniAb (OABI)

May 14, 2023 | finance.yahoo.com

OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially

See More Headlines

Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

OABI Company Calendar

Last Earnings: 8/10/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OABI
CUSIP: N/A
CIK: 1846253
Web: www.omniab.com
Phone: 510-250-7800
Fax: N/A
Employees: 95
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +92.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,330,000.00
Net Margins: N/A
Pretax Margin: -51.62%
Return on Equity: -6.38%
Return on Assets: -4.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.78
Quick Ratio: 4.78

Sales & Book Value

Annual Sales: $66.12 million
Price / Sales: 9.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.96 per share
Price / Book: 1.75

Miscellaneous

Outstanding Shares: 116,168,000
Free Float: 108,036,000
Market Cap: $602.91 million
Optionable: Not Optionable
Beta: -0.55

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Matthew W. Foehr (Age 50)
Pres, CEO & Director
Comp: $967.72k

Mr. Kurt A. Gustafson (Age 55)
Exec. VP of Fin. & CFO
Comp: $558.48k

Mr. Charles S. Berkman J.D. (Age 54)
Chief Legal Officer & Sec.
Comp: $734.33k

Ms. Cia McCaffrey
VP of People & Talent

Dr. Bill Harriman Ph.D.
Sr. VP of Antibody Discovery

Ms. Marie-Cecile van de Lavoir D.V.M.
Ph.D., Sr. VP of Technical Operations & Genetics

Dr. Christel Iffland Ph.D.
Sr. VP of Antibody Technologies

Dr. Douglas S. Krafte Ph.D. (Age 65)
Sr. VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head

Ms. Donna Ventura CPA
Sr. VP of Corp. Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OABI Stock - Frequently Asked Questions

Should I buy or sell OmniAb stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OABI shares.
View OABI analyst ratings or view top-rated stocks.
What is OmniAb's stock price forecast for 2023?: 9 Wall Street analysts have issued twelve-month target prices for OmniAb's shares. Their OABI share price forecasts range from $6.00 to $13.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 92.7% from the stock's current price.
View analysts price targets for OABI or view top-rated stocks among Wall Street analysts.
How have OABI shares performed in 2023?: OmniAb's stock was trading at $3.60 at the beginning of the year. Since then, OABI stock has increased by 44.2% and is now trading at $5.19.
View the best growth stocks for 2023 here.
When is OmniAb's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our OABI earnings forecast.

How were OmniAb's earnings last quarter?: OmniAb, Inc. (NASDAQ:OABI) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.04. The business earned $6.95 million during the quarter, compared to analyst estimates of $13.05 million.
What is OmniAb's stock symbol?: OmniAb trades on the NASDAQ under the ticker symbol "OABI."
How do I buy shares of OmniAb?: Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is OmniAb's stock price today?: One share of OABI stock can currently be purchased for approximately $5.19.
How much money does OmniAb make?: OmniAb (NASDAQ:OABI) has a market capitalization of $602.91 million and generates $66.12 million in revenue each year. The company earns $-22,330,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.
How can I contact OmniAb?: OmniAb's mailing address is 65 EAST 55TH STREET 18TH FLOOR, NEW YORK NY, 10022. The official website for the company is www.omniab.com. The company can be reached via phone at 510-250-7800 or via email at investors@omniab.com.

This page (NASDAQ:OABI) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial